Source: Fox News
Summary
Researchers at the Washington University School of Medicine in St. Louis have found that a simple blood test could predict a person’s risk of developing Alzheimer’s disease and estimate the year symptoms will begin. The test measures levels of a specific protein, p-tau217, which forms “tangles” in the brain that disrupt communication between nerve cells. The study analyzed data from over 600 older adults and found that p-tau217 levels rise in a consistent pattern long before memory loss begins. The team created a model that uses a patient’s age and protein levels to estimate when symptoms will appear, with a margin of error of three to four years.
Our Reading
The advice sounds familiar.
The guidance has been heard before, with a new study adding to the list of potential biomarkers for Alzheimer’s disease. The recommendation enters another phase, as researchers refine the test by researching other Alzheimer’s-linked proteins to narrow the margin of error. The study’s findings suggest that age and disease-related changes in the brain can influence how quickly Alzheimer’s symptoms become apparent. The results are still experimental and ripe for improvement, with the team hoping to refine the test and make it more accurate for clinical use.
It’s a familiar story: a new study, a new biomarker, and a promise of early detection and treatment. But the timeline for Alzheimer’s disease is long, and the journey from bench to bedside is often slow and winding.
Author: Evan Null
